RESEARKA

The central evidence is source-concentrated and preclinical. That is acceptable only for a frontier warning memo because the signal is counter-consensus and internally coherent: the same model/source reports plaque-cell reduction, EndoMT increase, and mortality risk. Contextual bundle papers cover adjacent senolytic biology, but the thesis should remain limited to advanced plaque biology and ABT-263 rather than general anti-aging use.

Citation Support

• source_1 Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
• source_2 Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts
• source_3 Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
• source_4 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice